title: [The usefulness of dopaminergic drugs in traumatic brain injury].
abstract: OBJECTIVE
  To review the bibliography indexed in MEDLINE so as to assess and/or compare the usefulness and indications of dopaminergic drugs in both cognitive and motor disorders due to head injuries (traumatic brain injury).
  
  
  METHODS
  Lesions due to head injuries cause both focal and diffuse cerebral damage which lead to neuropsychological and motor deficit. It is clear that motor alterations cause major physical disability, but neuropsychological alterations affect cognitive behaviour and emotional aspects which are very disabling and seriously affect both the patient and his family and also his return to social, family and working life. There is a wide range of drugs available to assist in the improvement or recovery of the patient. Some of the most important of these drugs are the dopaminergic agents, due to the importance of dopamine for proper frontal cerebral area function.
  
  
  CONCLUSIONS
  This study confirms the indications for the use of dopaminergeric drugs when trying to improve or accelerate recovery from cognitive deficits in patients with traumatic cerebral damage. However, it is important to note that, in view of the complexity of cognitive function and the mechanisms of their recovery, it will be necessary to make randomized, double blind, prospective studies with a control group (if possible) so as to determine the real part played by these drugs in the recovery process of patients with traumatic brain damage.
authors.affiliation: Unidad de Daño Cerebral, Institut Guttmann, Barcelona, España. metges@guttmann.com
authors.forename: F
authors.initials: F
authors.lastname: Orient-López
authors.forename: R
authors.initials: R
authors.lastname: Terre- Boliart
authors.forename: M
authors.initials: M
authors.lastname: Bernabeu-Guitart
authors.forename: S
authors.initials: S
authors.lastname: Ramón-Rona
authors.forename: A
authors.initials: A
authors.lastname: Pérez-Miras
mesh_terms: D000547:Amantadine / Q000627:therapeutic use; D001577:Benzophenones / Q000627:therapeutic use; D052160:Benzothiazoles; D001930:Brain Injuries / Q000150:complications / Q000188:drug therapy*; D001971:Bromocriptine / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D002396:Catechols / Q000627:therapeutic use; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D015259:Dopamine Agents / Q000627:therapeutic use*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007980:Levodopa / Q000627:therapeutic use; D009570:Nitriles; D009596:Nitrophenols; D000077487:Pramipexole; D012642:Selegiline / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D000077867:Tolcapone
chemical_list: D001577:Benzophenones; D052160:Benzothiazoles; D002396:Catechols; D015259:Dopamine Agents; D007211:Indoles; D009570:Nitriles; D009596:Nitrophenols; D013844:Thiazoles; C046649:ropinirole; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; C071192:entacapone; D000077487:Pramipexole; D000547:Amantadine; D000077867:Tolcapone; D002230:Carbidopa